Publications by authors named "Takashi Musha"
Background: Thrombolytic therapy is standard treatment in acute pulmonary thromboembolism (PTE) with hemodynamic instability. Although right heart thrombi (RHT) appear to increase mortality in acute PTE, large-scale studies of acute PTE with RHT are scarce.
Methods and results: Patient data (from August 2005 to May 2014) obtained from post-marketing surveillance of thrombolytic therapy using a tissue-type plasminogen activator were analyzed retrospectively.
Background: In Japan, the safety and efficacy of thrombolytic therapy using tissue-type plasminogen activator for acute pulmonary embolism (PE) in the real world remain unclear.
Methods And Results: A total of 1,254 patients with acute PE covered by the post-marketing surveillance of thrombolytic therapy using monteplase were divided into 3 groups: cardiopulmonary arrest (CPA)/collapse group (n=85); massive group, patients with unstable hemodynamics without CPA/collapse (n=217); and submassive group, patients with stable hemodynamics and right ventricular dysfunction (RVD) (n=465). In the efficacy analysis of 767 cases, the response rate to monteplase was 94.
Article Synopsis
- Thrombin activates cellular responses like platelet aggregation and smooth muscle cell proliferation via the PAR-1 receptor.
- The study evaluated E5555, a selective thrombin receptor antagonist, showing it effectively inhibits smooth muscle cell proliferation in both lab and rat models.
- E5555 demonstrated potential in reducing neointimal formation after vascular injury and could be beneficial for treating conditions like restenosis and chronic atherothrombotic disease.